What is HC Wainwright’s Estimate for APLS FY2024 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Research analysts at HC Wainwright reduced their FY2024 earnings estimates for shares of Apellis Pharmaceuticals in a research note issued to investors on Wednesday, November 6th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($1.79) for the year, down from their prior forecast of ($1.67). HC Wainwright has a “Buy” rating and a $57.00 price target on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.50) per share. HC Wainwright also issued estimates for Apellis Pharmaceuticals’ Q4 2024 earnings at ($0.49) EPS, Q1 2025 earnings at ($0.55) EPS, Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.73) EPS, FY2026 earnings at ($0.62) EPS, FY2027 earnings at $0.88 EPS and FY2028 earnings at $2.61 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The company had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business’s revenue was up 78.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.17) EPS.

Several other analysts also recently weighed in on the company. William Blair assumed coverage on Apellis Pharmaceuticals in a report on Wednesday, October 16th. They issued an “outperform” rating for the company. UBS Group dropped their price objective on shares of Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Wells Fargo & Company reduced their price objective on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a research note on Wednesday. Citigroup dropped their target price on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Robert W. Baird reduced their price target on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating for the company in a research report on Thursday. Six analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $51.06.

Apellis Pharmaceuticals Trading Up 4.3 %

APLS opened at $29.98 on Friday. Apellis Pharmaceuticals has a 52 week low of $24.34 and a 52 week high of $73.80. The company has a market capitalization of $3.73 billion, a P/E ratio of -14.77 and a beta of 0.87. The stock’s fifty day moving average is $31.02 and its two-hundred day moving average is $36.94. The company has a quick ratio of 4.18, a current ratio of 4.36 and a debt-to-equity ratio of 1.91.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. grew its holdings in shares of Apellis Pharmaceuticals by 191.9% during the third quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock worth $61,845,000 after buying an additional 1,409,707 shares in the last quarter. Iron Triangle Partners LP acquired a new position in Apellis Pharmaceuticals during the first quarter worth about $32,329,000. Fiera Capital Corp grew its stake in Apellis Pharmaceuticals by 47.7% during the 2nd quarter. Fiera Capital Corp now owns 1,401,190 shares of the company’s stock valued at $53,750,000 after acquiring an additional 452,753 shares in the last quarter. AQR Capital Management LLC raised its holdings in Apellis Pharmaceuticals by 337.3% in the 2nd quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock valued at $9,177,000 after acquiring an additional 190,420 shares during the last quarter. Finally, Redmile Group LLC purchased a new position in Apellis Pharmaceuticals in the 1st quarter worth approximately $9,111,000. 96.29% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the transaction, the director now owns 100,000 shares in the company, valued at $3,623,000. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).